Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. develops clinical-stage biotechnology programs for mental health conditions, with news centered on investigational therapies for treatment-resistant depression and social anxiety disorder. Recurring updates cover BPL-003, a mebufotenin benzoate nasal spray with FDA Breakthrough Therapy Designation for treatment-resistant depression; VLS-01, a DMT buccal film; and EMP-01, an oral R-MDMA program for social anxiety disorder.
Company announcements also address peer-reviewed clinical data, FDA interactions, patient-participant research practices, financial results, R&D spending, acquisition-related integration with Beckley Psytech, equity index inclusion, and capital runway disclosures. The news flow reflects a clinical-stage issuer whose operating updates are tied primarily to psychiatry-focused development programs, regulatory engagement, and financing capacity.
atai Life Sciences has priced its upsized initial public offering (IPO) at $15.00 per share, totaling 15,000,000 common shares and expected to raise $225.0 million. The offering is set to close on June 22, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 2,250,000 shares at the offering price. Trading on the Nasdaq Global Market under the symbol ATAI begins on June 18, 2021. This IPO is crucial for atai's future endeavors in mental health treatment innovations.
atai Life Sciences announced an initial public offering (IPO) of 14,286,000 common shares, priced between $13.00 and $15.00 each. The underwriters have a 30-day option to purchase an additional 2,142,900 shares. The offering aims to enhance atai's capabilities in mental health treatments using innovative therapies. The shares are set to list on the Nasdaq under the ticker symbol ATAI, with Credit Suisse, Citigroup, and others acting as book-running managers. A registration statement has been filed but is not yet effective.